Azenta, Inc.

Azenta, Inc.(AZTA)股票分析

$34.090

-2.267 (-6.65%)收盤時

Loading chart…
最高
37.368
開盤
36.520
成交量加權均價
34.83
成交量
1.26M
市值
2.81B
最低
33.030
成交金額
43.97M
企業價值/稅息折舊攤銷前利潤(TTM)
35.56

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software.

AI 分析 of Azenta, Inc. (AZTA)

賣出

Azenta Inc is not a good buy right now due to a current price of $34.09, which is significantly below the analyst price target of $35, indicating limited upside potential. Additionally, the stock has a low RSI of 31.611, suggesting it is oversold, but the recent 5-day change of -9.62% raises concerns about momentum. The main risk is the ongoing investigation by Rosen Law Firm regarding potential securities claims, which could further impact investor confidence.

估值指標

Azenta, Inc.(AZTA)目前預期本益比為 29.07,5 年平均預期本益比為 186.71。

預期本益比

合理
5 年均值 P/E
186.71
目前P/E
29.07
高估
487.43
低估
-114.00

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
29.69
目前EV/EBITDA
35.56
高估
68.03
低估
-8.64

預期股價營收比

合理
5 年均值 P/S
4.86
目前P/S
2.51
高估
8.06
低估
1.66

Alphio AI 對 AZTA 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%AZTA

$34.77

情境價格

基

基準

基準 · 50%AZTA

$30.40

情境價格

悲

悲觀

悲觀 · 25%AZTA

$25.27

情境價格

持有 AZTA 的大戶

A

American Capital Management, Inc.

+ 持有AZTA

+1.32%

3個月報酬率

事件時間軸

2026-08-24 (ET)

08:30:00

Azenta Appoints Martin Madaus as Interim CEO

08:30:00

Company Reaffirms Q4 Total Revenue Guidance

2026-08-04 (ET)

17:00:00

Company Expects Organic Revenue Flat to Up 1% for FY2025

17:00:00

Total Organic Revenue Expected to Decline in Q4 FY2025

17:00:00

Company Q3 Revenue Exceeds Expectations at $161M

資訊

AZTA 常見問題 —— 由 Alphio AI 解答

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software. It operates in the Healthcare sector (SPECIAL INDUSTRY MACHINERY, NEC industry).

Azenta Inc is not a good buy right now due to a current price of $34.09, which is significantly below the analyst price target of $35, indicating limited upside potential. Additionally, the stock has a low RSI of 31.611, suggesting it is oversold, but the recent 5-day change of -9.62% raises concerns about momentum. The main risk is the ongoing investigation by Rosen Law Firm regarding potential securities claims, which could further impact investor confidence.

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易